138 related articles for article (PubMed ID: 8427869)
1. Halofuginone: an inhibitor of collagen type I synthesis.
Granot I; Halevy O; Hurwitz S; Pines M
Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
[TBL] [Abstract][Full Text] [Related]
2. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone.
Granot I; Bartov I; Plavnik I; Wax E; Hurwitz S; Pines M
Poult Sci; 1991 Jul; 70(7):1559-63. PubMed ID: 1886867
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of rat renal fibroblast proliferation by halofuginone.
Haran N; Leschinski L; Pines M; Rapoport J
Nephron Exp Nephrol; 2006; 104(1):e35-40. PubMed ID: 16735800
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone.
Nagler A; Katz A; Aingorn H; Miao HQ; Condiotti R; Genina O; Pines M; Vlodavsky I
Kidney Int; 1997 Dec; 52(6):1561-9. PubMed ID: 9407501
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
7. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone: a novel antifibrotic therapy.
Pines M; Nagler A
Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone and insulin-like growth factor I regulate collagen gene expression and extracellular collagen in cultures of avian skin fibroblasts.
Granot I; Halevy O; Hurwitz S; Pines M
Mol Cell Endocrinol; 1991 Sep; 80(1-3):1-9. PubMed ID: 1659542
[TBL] [Abstract][Full Text] [Related]
10. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Nagler A; Genina O; Lavelin I; Ohana M; Pines M
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
[TBL] [Abstract][Full Text] [Related]
11. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
Nagler A; Miao HQ; Aingorn H; Pines M; Genina O; Vlodavsky I
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):194-202. PubMed ID: 9012656
[TBL] [Abstract][Full Text] [Related]
13. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
17. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
Levi-Schaffer F; Nagler A; Slavin S; Knopov V; Pines M
J Invest Dermatol; 1996 Jan; 106(1):84-8. PubMed ID: 8592087
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
20. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
